tbuckley/cabot-search huggingface dataset:
Further refinement of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure using classical test theory and item response theory
Authors: Rachael Pattinson, Nirohshah Trialonis-Suthakharan, Tim Pickles, Jennifer Austin, Allison FitzGerald, Matthias Augustin, Christine Bundy
Journal: British Journal of Dermatology (2023)

Abstract Background Existing dermatology-specific Patient-Reported Outcome Measures (PROMs) do not fully capture the substantial physical, psychological and social impact of dermatological conditions on patients’ lives and are not recommended for use according to the COSMIN criteria. Most were developed with insufficient patient involvement and relied on classical psychometric methods. We are developing the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure for use in research and clinical practice in partnership with patients. Objectives To examine the factor structure of PRIDD, determine the definitive selection of items for each subscale, and establish structural validity and internal consistency through classical and modern psychometric methods. Methods Two cross-sectional online surveys were conducted. Adults (≥ 18 years) worldwide living with a dermatological condition were recruited through the membership network of the International Alliance of Dermatology Patient Organizations (GlobalSkin). They completed the PRIDD questionnaire and a demographics questionnaire via an online survey. We examined missing data and distribution of scores for each item. The factor structure was assessed using confirmatory and exploratory factor analysis (Survey 1). Internal consistency was examined using Cronbach’s α. Rasch measurement theory analyses were conducted, including iterative assessment of rating scale function, fit to the Rasch model, unidimensionality, reliability, local dependence, targeting and differential item functioning (DIF) (Surveys 1 and 2). Results Participants in Surveys 1 and 2 numbered 483 and 504 people, respectively. All items had ≤ 3% missing scores and all five response options were used. A four-factor model showed the best fit. PRIDD and all four subscales were internally consistent but showed some misfit to the Rasch measurement model. Adjustments were made to rectify disordered thresholds, remove misfitting items, local dependency and DIF, and improve targeting. The resulting 16-item version and subscales fit the Rasch model, showed no local dependency or DIF at the test level, and were well targeted. Conclusions This field test study produced the final PRIDD measure, consisting of 16 items across four domains. The data triangulated and refined the conceptual framework of impact and provide evidence of PRIDD’s structural validity and internal consistency. The final step in the development and validation of the PRIDD measure is to test the remaining measurement properties.
Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial
Authors: Marleen M L van Arnhem, Bart van den Munckhof, Alexis Arzimanoglou, Emilio Perucca, Liisa Metsähonkala, Guido Rubboli, Marianne Søndergaard Khinchi, Anne de Saint-Martin, Kerstin A Klotz, Julia Jacobs, J Helen Cross, Irene Garcia Morales, Wim M Otte, Heleen C van Teeseling, Frans S S Leijten, Kees P J Braun, Floor E Jansen, Anna Jansen, Lieven Lagae, Thomas Bast, Sarah von Spiczak, Gerhard Kluger, Patrick van Bogaert, Eija Gaily, Sarah Baer, Stéphane Auvin, Richard Chin, Sameer Zuberi, Petia Dimova, C Dana Craiu, Pierangelo Veggiotti, Georgia Ramantani
Journal: The Lancet Neurology (2023)
Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study
Authors: Jaimie Z Shing, Eric A Engels, April A Austin, Megan A Clarke, Jennifer H Hayes, Aimée R Kreimer, Analise Monterosso, Marie-Josèphe Horner, Karen S Pawlish, Qianlai Luo, Elizabeth R Zhang, Aimee J Koestler, Ruth M Pfeiffer, Meredith S Shiels
Journal: The Lancet HIV (2023)
Development and validation of open-source deep neural networks for comprehensive chest x-ray reading: a retrospective, multicentre study
Authors: Yashin Dicente Cid, Matthew Macpherson, Louise Gervais-Andre, Yuanyi Zhu, Giuseppe Franco, Ruggiero Santeramo, Chee Lim, Ian Selby, Keerthini Muthuswamy, Ashik Amlani, Heath Hopewell, Das Indrajeet, Maria Liakata, Charles E Hutchinson, Vicky Goh, Giovanni Montana
Journal: The Lancet Digital Health (2023)

Artificial intelligence (AI) systems for automated chest x-ray interpretation hold promise for standardising reporting and reducing delays in health systems with shortages of trained radiologists. Yet, there are few freely accessible AI systems trained on large datasets for practitioners to use with their own data with a view to accelerating clinical deployment of AI systems in radiology. We aimed to contribute an AI system for comprehensive chest x-ray abnormality detection.
MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial
Authors: Burak Görgec, Ingrid S Hansen, Gunter Kemmerich, Trygve Syversveen, Mohammed Abu Hilal, Eric J T Belt, Koop Bosscha, Mark C Burgmans, Vincent C Cappendijk, Mathieu D'Hondt, Bjørn Edwin, Arian R van Erkel, Hugo A J Gielkens, Dirk J Grünhagen, Paul D Gobardhan, Henk H Hartgrink, Karin Horsthuis, Elisabeth G Klompenhouwer, Niels F M Kok, Peter A M Kint, Koert Kuhlmann, Wouter K G Leclercq, Daan J Lips, Bart Lutin, Monique Maas, Hendrik A Marsman, Martijn Meijerink, Yannick Meyer, Mario Morone, Jan Peringa, Jasper P Sijberden, Otto M van Delden, Janneke E van den Bergh, Inge J S Vanhooymissen, Maarten Vermaas, François E J A Willemssen, Marcel G W Dijkgraaf, Patrick M Bossuyt, Rutger-Jan Swijnenburg, Åsmund A Fretland, Cornelis Verhoef, Marc G Besselink, Jaap Stoker, Ninos Ayez, Claudio Bnà, Rivka van den Boom, Doenja J.M. Lambregts, Gerrit-Jan Liefers, Celine de Meyere, Werner A. Draaisma, Michael F. Gerhards, Farshad Imani, Theo .J.M. Ruers, Mike S.L. Liem, Gian Piero Serafino, Hermen C. van Beek, Joost A.B. van der Hoeven, Cornelis J. Veeken, Babs M. Zonderhuis
Journal: The Lancet Oncology (2023)
Genetic basis of pregnancy-associated decreased platelet counts and gestational thrombocytopenia
Authors: Zijing Yang, Liang Hu, Jianxin Zhen, Yuqin Gu, Yanhong Liu, Shang Huang, Yuandan Wei, Hao Zheng, Xinxin Guo, Guo-Bo Chen, Yan Yang, Likuan Xiong, Fengxiang Wei, Siyang Liu
Journal: Blood (2023)

Platelet count reduction occurs throughout pregnancy, with 5% to 12% of pregnant women being diagnosed with gestational thrombocytopenia (GT), characterized by a more marked decrease in platelet count during pregnancy. However, the underlying biological mechanism behind these phenomena remains unclear. Here, we used sequencing data from noninvasive prenatal testing of 100 186 Chinese pregnant individuals and conducted, to our knowledge, the hitherto largest-scale genome-wide association studies on platelet counts during 5 periods of pregnancy (the first, second, and third trimesters, delivery, and the postpartum period) as well as 2 GT statuses (GT platelet count < 150 × 109/L and severe GT platelet count < 100 × 109/L). Our analysis revealed 138 genome-wide significant loci, explaining 10.4% to 12.1% of the observed variation. Interestingly, we identified previously unknown changes in genetic effects on platelet counts during pregnancy for variants present in PEAR1 and CBL, with PEAR1 variants specifically associated with a faster decline in platelet counts. Furthermore, we found that variants present in PEAR1 and TUBB1 increased susceptibility to GT and severe GT. Our study provides insight into the genetic basis of platelet counts and GT in pregnancy, highlighting the critical role of PEAR1 in decreasing platelet counts during pregnancy and the occurrence of GT. Those with pregnancies carrying specific variants associated with declining platelet counts may experience a more pronounced decrease, thereby elevating the risk of GT. These findings lay the groundwork for further investigation into the biological mechanisms and causal implications of GT.
Demographics of sources of HIV-1 transmission in Zambia: a molecular epidemiology analysis in the HPTN 071 PopART study
Authors: Matthew Hall, Tanya Golubchik, David Bonsall, Lucie Abeler-Dörner, Mohammed Limbada, Barry Kosloff, Ab Schaap, Mariateresa de Cesare, George MacIntyre-Cockett, Newton Otecko, William Probert, Oliver Ratmann, Ana Bulas Cruz, Estelle Piwowar-Manning, David N Burns, Myron S Cohen, Deborah J Donnell, Susan H Eshleman, Musonda Simwinga, Sarah Fidler, Richard Hayes, Helen Ayles, Christophe Fraser, Yaw Agyei, Nulda Beyers, Peter Bock, Virginia Bond, Justin Bwalya, Anne Cori, Anneen Deventer, Rory Dunbar, Wafaa El-Sadr, Lynda Emel, Sian Floyd, Sam Griffith, James Hargreaves, Katharina Hauck, Tanette Headen, Graeme Hoddinott, Anelet James, Karen Jennings, Sarah Kanema, Barry Kosloff, James Kruger, Ramya Kumar, David Macleod, Nozizwe Makola, Nomtha Mandla, Eric Miller, Ayana Moore, Lawrence Mwenge, Heather Noble, Mwelwa Phiri, Michael Pickles, Kalpana Sabapathy, Ephraim Sakala, Rafael Sauter, Kwame Shanaube, Andrew Silumesi, Nirupama Sista, Tim Skalland, Peter Smith, Ranjeeta Thomas, Sten Vermund, Rhonda White, Ethan Wilson, Blia Yang, Krista Yuhas, Rory Bowden, Vincent Calvez, Max Essex, Kate Grabowski, Ravindra Gupta, Joshua Herbeck, Joseph Kagaayi, Pontiano Kaleebu, Jairam Lingappa, Sikhulile Moyo, Vladimir Novitsky, Thumbi Ndung’u, Deenan Pillay, Thomas Quinn, Andrew Rambaut, Janet Seeley, Deogratius Ssemwanga, Frank Tanser, Maria Wawer
Journal: The Lancet Microbe (2023)

In the last decade, universally available antiretroviral therapy (ART) has led to greatly improved health and survival of people living with HIV in sub-Saharan Africa, but new infections continue to appear. The design of effective prevention strategies requires the demographic characterisation of individuals acting as sources of infection, which is the aim of this study.
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
Authors: Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Müller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2023)

The World Health Organization (WHO) classification of hematolymphoid tumors and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of chronic myelomonocytic leukemia (CMML). To assess its qualitative and quantitative implications for patient care, we started with 3311 established CMML cases (according to WHO 2017 criteria) and included 2130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both 2022 classification systems, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as myelodysplastic syndrome (MDS) according to the WHO 2017 classification. Importantly, 1.5 times more oligomonocytosis cases were classified as CMML according to WHO 2022 than based on ICC, because of different diagnostic criteria. Genetic analyses of the newly classified CMML cases showed a distinct mutational profile with strong enrichment of MDS-typical alterations, resulting in a transcriptional subgroup separated from established MD and myeloproliferative CMML. Despite a different cytogenetic, molecular, immunophenotypic, and transcriptional landscape, no differences in overall survival were found between newly classified and established MD-CMML cases. To the best of our knowledge, this study represents the most comprehensive analysis of routine CMML cases to date, both in terms of clinical characterization and transcriptomic analysis, placing newly classified CMML cases on a disease continuum between MDS and previously established CMML.
Central Visual Field Testing in Early Glaucoma
Authors: Darrell WuDunn, Hana L. Takusagawa, Jullia A. Rosdahl, Arthur J. Sit, Vikas Chopra, Yvonne Ou, Grace M. Richter, O’Rese J. Knight, David Solá-Del Valle, Stephen J. Kim
Journal: Ophthalmology (2023)
Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis
Authors: Stephanie Jost, Olivier Lucar, Esther Lee, Taylor Yoder, Kyle Kroll, Sho Sugawara, Scott Smith, Rhianna Jones, George Tweet, Alexandra Werner, Phillip J. Tomezsko, Haley L. Dugan, Joshua Ghofrani, Philippe Rascle, Marcus Altfeld, Michaela Müller-Trutwin, Paul Goepfert, R. Keith Reeves
Journal: Science Immunology (2023)

Multiple studies have broadened the roles of natural killer (NK) cells functioning as purely innate lymphocytes by demonstrating that they are capable of putative antigen-specific immunological memory against multiple infectious agents including HIV-1 and influenza. However, the mechanisms underlying antigen specificity remain unknown. Here, we demonstrate that antigen-specific human NK cell memory develops upon exposure to both HIV and influenza, unified by a conserved and epitope-specific targetable mechanism largely dependent on the activating CD94/NKG2C receptor and its ligand HLA-E. We validated the permanent acquisition of antigen specificity by individual memory NK cells by single-cell cloning. We identified elevated expression of KLRG1, α4β7, and NKG2C as biomarkers of antigen-specific NK cell memory through complex immunophenotyping. Last, we uncovered individual HLA-E-restricted peptides that may constitute the dominant NK cell response in HIV-1- and influenza-infected persons in vivo. Our findings clarify the mechanisms contributing to antigen-specific memory NK cell responses and suggest that they could be potentially targeted therapeutically for vaccines or other therapeutic interventions.
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Authors: Curtis Cai, Yu Gao, Sarah Adamo, Olga Rivera-Ballesteros, Lotta Hansson, Anders Österborg, Peter Bergman, Johan K. Sandberg, Hans-Gustaf Ljunggren, Niklas K. Björkström, Kristoffer Strålin, Sian Llewellyn-Lacey, David A. Price, Chuan Qin, Alba Grifoni, Daniela Weiskopf, E. John Wherry, Alessandro Sette, Soo Aleman, Marcus Buggert
Journal: Science Immunology (2023)

T cells are critical for immune protection against severe COVID-19, but it has remained unclear whether repeated exposure to SARS-CoV-2 antigens delivered in the context of vaccination fuels T cell exhaustion or reshapes T cell functionality. Here, we sampled convalescent donors with a history of mild or severe COVID-19 before and after SARS-CoV-2 vaccination to profile the functional spectrum of hybrid T cell immunity. Using combined single-cell technologies and high-dimensional flow cytometry, we found that the frequencies and functional capabilities of spike-specific CD4
Injury and illness among Norwegian Olympic athletes during preparation for five consecutive Summer and Winter Games
Authors: Benjamin Clarsen, Hilde Moseby Berge, Fredrik Bendiksen, Bjørn Fossan, Hilde Fredriksen, Lars Haugvad, Mona Kjelsberg, Ola Ronsen, Kathrin Steffen, Thomas Torgalsen, Roald Bahr
Journal: British Journal of Sports Medicine (2023)

To describe the patterns of health problems among Norwegian Olympic candidates during their preparations for five consecutive Olympic Games (London 2012, Sochi 2014, Rio de Janeiro 2016, PyeongChang 2018 and Tokyo 2020).This was a descriptive epidemiological study using the Oslo Sports Trauma Research Center Questionnaire on Health Problems to collect data on all self-reported health problems from Norwegian Olympic candidate athletes for 12-18 months prior to each Olympic Games. Team physicians and physiotherapists followed up the athlete reports, providing clinical care and classifying reported problems according to the International Olympic Committee 2020 consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport.Between 2011 and 2020, 533 athletes were included in the Norwegian Olympic team monitoring programme, with a 78% response to the weekly questionnaire. During this time, athletes reported 2922 health problems, including 1409 illnesses (48%), 886 overuse injuries (repetitive mechanism, 30%) and 627 acute injuries (traumatic mechanism, 21%). Diagnostic codes were recorded for 2829 (97%) of health problems. Athletes reported, on average, 5.9 new health problems per year (95% CI: 5.6 to 6.1), including 1.3 acute injuries (CI: 1.2 to 1.4), 1.7 overuse injuries (CI: 1.6 to 1.9) and 2.9 illnesses (CI: 2.7 to 3.0). Each year, female and male athletes lost an average of 40 and 26 days of training and competition due to health problems, respectively. The diagnoses with the highest health burden were anterior cruciate ligament rupture, respiratory infection, lumbar pain and patellar tendinopathy.The injury burden was particularly high among female athletes and in team sports, whereas endurance sports had the greatest burden of illness. Our data provide a compelling argument for prioritising medical care and investing in prevention programmes not just during the Olympic Games, but also the preparation period.
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
Authors: Désirée van der Heijde, Anna Molto, Sofia Ramiro, Jürgen Braun, Maxime Dougados, Floris A van Gaalen, Lianne S Gensler, Robert D Inman, Robert B M Landewé, Helena Marzo-Ortega, Victoria Navarro-Compán, Andri Phoka, Denis Poddubnyy, Mikhail Protopopov, John Reveille, Martin Rudwaleit, Percival Sampaio-Barros, Alexandre Sepriano, Joachim Sieper, Filip E Van den Bosch, Irene van der Horst-Bruinsma, Pedro M Machado, Xenofon Baraliakos
Journal: Annals of the Rheumatic Diseases (2023)

Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible on radiographs. The Assessment of SpondyloArthritis international Society, representing a worldwide group of experts reached consensus on changes in the nomenclature pertaining to axial spondyloarthritis (axSpA), such as the terminology of diagnosis and of assessment of disease activity tools. These are important changes in the field, as experts in axSpA are now in agreement that the term axSpA is the overall term for the disease. A further differentiation, of which radiographic versus non-radiographic is only one aspect, may be relevant for research purposes. Another important decision was that the terms AS and radiographic axSpA (r-axSpA) can be used interchangeably, but that the preferred term is r-axSpA. Based on the decision that axSpA is the correct terminology, a proposal was made to officially change the meaning of the ASDAS acronym to ‘Axial Spondyloarthritis Disease Activity Score’. In addition, for simplification it was proposed that the term ASDAS (instead of ASDAS-CRP) should be preferred and applied to the ASDAS calculated with C reactive protein (CRP). It is hoped that these changes will be used consequently for education, in textbooks, manuscripts and presentations.
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
Authors: Romain Aymon, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Diederik De Cock, Lene Dreyer, Ori Elkayam, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Suleyman Serdar KOCA, Tore K Kvien, Burkhard F Leeb, Galina Lukina, Dan C Nordström, Karel Pavelka, Manuel Pombo-Suarez, Ana Rodrigues, Ziga Rotar, Anja Strangfeld, Patrick Verschueren, Rasmus Westermann, Jakub Zavada, Delphine Sophie Courvoisier, Axel Finckh, Kim Lauper
Journal: Annals of the Rheumatic Diseases (2023)

In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept.
Chemically Tailored Single Atoms for Targeted and Light‐Controlled Bactericidal Activity
Authors: Zaoming Li, Zhiqiang Zhao, Shutong Chen, Wenjie Wu, Ying Jin, Junjie Mao, Yuqing Lin, Ying Jiang
Journal: Advanced Healthcare Materials (2023)

Single-atom (SA) nanoparticles exhibit considerable potential in terms of photothermal properties for bactericidal applications. Nevertheless, the restricted efficacy of their targeted and controlled antibacterial activity has hindered their practical implementation. This study aims to overcome this obstacle by employing chemical modifications to tailor SAs, thereby achieving targeted and light-controlled antimicrobial effects. By conducting atomic-level modifications on palladium SAs using glutathione (GSH) and mercaptophenylboronic acid (MBA), their superior targeted binding capabilities toward Escherichia coli cells are demonstrated, surpassing those of SAs modified with cysteine (Cys). Moreover, these modified SAs effectively inhibit wound bacteria proliferation and promote wound healing in rats, without inducing noticeable toxicity to major organs under 808 nm laser irradiation. This study highlights the significance of chemical engineering in tailoring the antibacterial properties of SA nanoparticles, opening avenues for combating bacterial infections and advancing nanoparticle-based therapies.